Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02134028 · ClinicalTrials.gov registry record · Phase 3
Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE)
A Phase 3 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,282
- Enrollment target
NCT02134028 is a Phase 3 study that has completed, run by Sanofi. The registered enrollment target is 2,282 participants.
The verdict
NCT02134028, a Phase 3 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,282 participants
- Enrollment target
Study Summary
Primary Objective: To evaluate the long-term safety and tolerability of dupilumab in participants with asthma who participated in a previous dupilumab asthma study (DRI12544, PDY14192, EFC13579, EFC13691). Secondary Objectives: To evaluate the long-term efficacy of dupilumab in participants with asthma who participated in a previous dupilumab asthma clinical study. To evaluate dupilumab in participants with asthma who participated in a previous dupilumab asthma clinical study, with regards to: * Systemic exposure * Anti-drug antibodies * Biomarkers
Interventions
- DRUG Dupilumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,282 participants |
| Start Date | 2014-08-05 |
| Est. Completion | 2019-10-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02134028
The ClinicalTrials.gov registry entry for NCT02134028 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,282 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dupilumab is the first listed.
NCT02134028 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02134028 about?
NCT02134028 is a clinical study titled "Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE)". Primary Objective: To evaluate the long-term safety and tolerability of dupilumab in participants with asthma who participated in a previous dupilumab asthma study (DRI12544, PDY14192, EFC13579, EFC13691). Secondary Objectives: To evaluate the long-term efficacy of dupilumab in participants with ...
What is the current status of trial NCT02134028?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,282 participants. The study started on 2014-08-05. Estimated completion is 2019-10-11.
What interventions are being tested in trial NCT02134028?
The interventions under investigation include: Dupilumab (DRUG).
Who is sponsoring clinical trial NCT02134028?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.